Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026...
Mike Andriole Marcd Kozin Patrick Machado Oncology Consortium Therapeutic Goods Administration National Institutes Of Health
Source: businessinsider.com